2020
Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability
Duy PQ, He M, He Z, Kahle KT. Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability. Expert Opinion On Therapeutic Targets 2020, 24: 629-637. PMID: 32336175, PMCID: PMC8104019, DOI: 10.1080/14728222.2020.1762174.Peer-Reviewed Original ResearchConceptsNeuronal hyperexcitabilityKCC2 functionSynaptic inhibitionKCC2 activityPreclinical insightsRole of KCC2Treatment of epilepsyCommon neurological disorderNovel therapeutic strategiesPotential adverse effectsDrug targetsKCC2 dysfunctionSeizure reductionUnprovoked seizuresIntractable epilepsySeizure activityEpilepsy therapyCotransporter KCC2Clinical urgencyPreclinical proofTherapeutic benefitTherapeutic strategiesNew drug targetsTherapeutic targetingKCC2
2019
Identification of KCC2 Mutations in Human Epilepsy Suggests Strategies for Therapeutic Transporter Modulation
Duy PQ, David WB, Kahle KT. Identification of KCC2 Mutations in Human Epilepsy Suggests Strategies for Therapeutic Transporter Modulation. Frontiers In Cellular Neuroscience 2019, 13: 515. PMID: 31803025, PMCID: PMC6873151, DOI: 10.3389/fncel.2019.00515.Peer-Reviewed Original ResearchHuman epilepsySignificant drug-related adverse effectsDrug-related adverse effectsMedication-refractory epilepsyDevelopment of epilepsyCommon neurological disorderPotential therapeutic strategyKCC2 dysfunctionNeuronal hyperexcitabilityGABA inhibitionGABAergic inhibitionSeizure disorderUnprovoked seizuresImpaired balanceKCC2 activityNeuronal excitabilityNeuronal excitationTherapeutic strategiesTransporter modulationEpileptic seizuresEpilepsyNeurological disordersChloride homeostasisSatisfactory treatmentAdverse effects